• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Roles of HDAC1/3 effecting on metabolic shift in myeloma cells; Development of a novel treatment strategy targeting metabolic shift

Research Project

Project/Area Number 18K16118
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 54010:Hematology and medical oncology-related
Research InstitutionThe University of Tokushima

Principal Investigator

HARADA Takeshi  徳島大学, 病院, 特任助教 (10618359)

Project Period (FY) 2018-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords血液腫瘍学 / 腫瘍メタボリズム / HDAC / Cancer metabolism
Outline of Final Research Achievements

We here investigated the biological significance of class-I histone deacetylases (HDACs), especially HDAC1 and HDAC3 in multiple myeloma (MM). We first revealed the downregulation of IRF4 and PIM2, which are the master transcription factor and the regulator of tumor metabolism, respectively, in the HDAC1-knockdown MM cells compared to control cells or HDAC3-knockdown cells. In addition, we delineated the mechanisms of constitutively high expression of PIM2 by the intrinsic HDAC1-IRF4 axis in MM cells. Furthermore, PIM2 was upregulated by the extrinsic myeloma-related microenvironmental factor such as IL-6. Finally, we developed the novel treatment strategy of combination of class-I HDAC inhibitor MS-275 with the PIM inhibitor SMI-16a in vitro and in vivo analysis. Taken together, our findings suggested that MM cell metabolism is regulated by PIM2, which are governed by the HDAC1-IRF4 intrinsic pathway and the myeloma niche-related extrinsic one.

Academic Significance and Societal Importance of the Research Achievements

HDACは遺伝子発現抑制に働くエピゲノム因子として知られているが、骨髄腫細胞では、HDAC1が高発現しているにも関わらず、腫瘍では種々の遺伝子が高発現している。本研究では、骨髄腫細胞でHDAC1によるIRF4およびPIM2の発現維持機構の一端を解明し、HDAC1による遺伝子発現制御に関する新たな知見を提唱した点に学術的意義がある。また、骨髄腫に対するクラスI HDACとPIMを標的とする併用療法の開発を行い、HDACアイソフォームの役割を明らかにしながらメタボリックシフトを標的とする治療法の開発に繋げた本研究は、他の悪性疾患にも応用可能な研究であり、社会的意義を有すると考えられる。

Report

(3 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • Research Products

    (11 results)

All 2019 2018

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 2 results) Presentation (8 results) (of which Int'l Joint Research: 2 results,  Invited: 2 results)

  • [Journal Article] PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.2019

    • Author(s)
      Iwasa Masami、Harada Takeshi、Oda Asuka、Bat-Erdene Ariunzaya、Teramachi Jumpei、Tenshin Hirofumi、Ashtar Mohannad、Oura Masahiro、Sogabe Kimiko、Udaka Kengo、Fujii Shiro、Nakamura Shingen、Miki Hirokazu、Kagawa Kumiko、Ozaki Shuji、Abe Masahiro
    • Journal Title

      Oncotarget

      Volume: 10 Issue: 20 Pages: 1903-1917

    • DOI

      10.18632/oncotarget.26726

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling2019

    • Author(s)
      Ho Matthew、Chen Tianzeng、Liu Jiye、Dowling Paul、Hideshima Teru、Zhang Li、Morelli Eugenio、Camci-Unal Gulden、Wu Xinchen、Tai Yu-Tzu、Wen Kenneth、Samur Mehmet、Schlossman Robert L.、Mazitschek Ralph、Kavanagh Emma L.、Lindsay Sinead、Harada Takeshi、McCann Amanda、Anderson Kenneth C.、O’Gorman Peter、Bianchi Giada
    • Journal Title

      Leukemia

      Volume: 34 Issue: 1 Pages: 196-209

    • DOI

      10.1038/s41375-019-0493-x

    • NAID

      120006999404

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA2018

    • Author(s)
      Bat-Erdene Ariunzaya、Nakamura Shingen、Oda Asuka、Iwasa Masami、Teramachi Jumpei、Ashtar Mohannad、Harada Takeshi、Miki Hirokazu、Tenshin Hirofumi、Hiasa Masahiro、Fujii Shiro、Sogabe Kimiko、Oura Masahiro、Udaka Kengo、Kagawa Kumiko、Yoshida Sumiko、Aihara Ken-ichi、Kurahashi Kiyoe、Endo Itsuro、Abe Masahiro
    • Journal Title

      British Journal of Haematology

      Volume: 印刷中 Issue: 5 Pages: 969-974

    • DOI

      10.1111/bjh.15673

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] The novel therapeutic strategy targeting the HDAC1-IRF4-PIM2 pathway in myeloma cells.2019

    • Author(s)
      Harada T, Oda A, Tenshin H, Teramachi J, Oura M, Sogabe K, Iwasa M, Fujii S, Nakamura S, Miki H, Kagawa K, Hideshima T, Anderson KC, Abe M.
    • Organizer
      The 44rd Annual Meeting of the Japanese Society of Myeloma
    • Related Report
      2019 Annual Research Report
  • [Presentation] Targeting myeloma metabolisoms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy.2019

    • Author(s)
      Harada T, Oda A, Tenshin H, Teramachi J, Oura M, Sogabe K, Fujii S, Nakamura S, Miki H, Kagawa K, Ozaki S, Hideshima T, Anderson KC, Abe M.
    • Organizer
      The 17th International Myeloma Workshop
    • Related Report
      2019 Annual Research Report
  • [Presentation] 多発性骨髄腫におけるHDACアイソフォームの役割とその選択的阻害による治療法の開発2019

    • Author(s)
      原田武志
    • Organizer
      第81回日本血液学会学術集会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] Novel therapeutic rationale for targeting HDAC1 and PIM2 in multiple myeloma.2019

    • Author(s)
      Harada T, Oda A, Ohguchi H, Grondin Y, Tenshin H, Hiasa M, Teramachi J, Oura M, Sogabe K, Fujii S, Nakamura S, Miki H, Kagawa K, Ozaki S, Hideshima T, Anderson KC, Abe M.
    • Organizer
      The 61th Annual Meeting of the American Society of Hematology
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death2018

    • Author(s)
      Harada T, Oda A, Teramachi J, Bat-Erdene A, Iwasa M, Maeda Y, Nakamura S, Oura M, Fujii S, Miki H, Kagawa K, Hideshima T, Anderson KC, Abe M
    • Organizer
      The 43rd Annual Meeting of the Japanese Society of Myeloma
    • Related Report
      2018 Research-status Report
  • [Presentation] Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis2018

    • Author(s)
      Harada T, Oda A, Teramachi J, Bat-Erdene A, Iwasa M, Oura M, Nakamura S, Kagawa K, Okamoto Y, Sogabe K, Fujii S, Miki H, Ozaki S, Hideshima T, Anderson KC, Abe M
    • Organizer
      The 9th JSH International Symposium 2018 in Kyoto
    • Related Report
      2018 Research-status Report
  • [Presentation] Roles of HDAC1 and HDAC3 as therapeutic targets against myeloma cells2018

    • Author(s)
      Harada T
    • Organizer
      The 80th Annual Meeting of the Japanese Society of Hematology
    • Related Report
      2018 Research-status Report
    • Invited
  • [Presentation] The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis2018

    • Author(s)
      Harada T, Oda A, Grondin Y, Teramachi J, Bat-Erdene A, Iwasa M, Oura M, Nakamura S, Kagawa K, Okamoto Y, Sogabe K, Fujii S, Miki H, Ozaki S, Hideshima T, Anderson KC, Abe M
    • Organizer
      The 60th ASH Annual Meeting & Exposition
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2018-04-23   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi